Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.
Gregorc
Vanesa
V
Department of Oncology, Scientific Institute University Hospital San Raffaele, Milan. vanesa@hsr.it
Ceresoli
Giovanni Luca
GL
Floriani
Irene
I
Spreafico
Anna
A
Bencardino
Katia Bruna
KB
Ludovini
Vienna
V
Pistola
Lorenza
L
Mihaylova
Zhasmina
Z
Tofanetti
Francesca Romana
FR
Ferraldeschi
Massimiliano
M
Torri
Valter
V
Cappuzzo
Federico
F
Crinò
Lucio
L
Tonato
Maurizio
M
Villa
Eugenio
E
D000230:Adenocarcinoma / Q000097:blood / Q000235:genetics; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000235:genetics; D018450:Disease Progression; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D066246:ErbB Receptors / Q000097:blood*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D017434:Protein Structure, Tertiary; D011799:Quinazolines / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000077156:Gefitinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases